



Liste des publications IUCT-O/CRCT

Mai 2022

1. Albisinni, S., Diamand, R., Mjaess, G., Aoun, F., Assenmacher, G., Assenmacher, C., Verhoest, G., Holz, S., Naudin, M., Ploussard, G., Mari, A., Minervini, A., Tay, A., Issa, R., Roumigué, M., Bajeot, A. S., Simone, G., Anceschi, U., Umari, P., Sridhar, A., ... Roumeguère, T. (2022). **Defining the Morbidity of Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Adoption of the Comprehensive Complication Index.** *Journal of endourology*, 36(6), 785–792. (IF : 2,942. CAT : C) <https://doi.org/10.1089/end.2021.0843>
2. Angeles, M. A., Hernández, A., Pérez-Benavente, A., Cabarro, B., Spagnolo, E., Rychlik, A., Daboussi, A., Migliorelli, F., Bétrian, S., Ferron, G., Gil-Moreno, A., Guyon, F., & Martinez, A. (2022). **The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.** *Gynecologic oncology*, S0090-8258(22)00278-5. Advance online publication. (IF : 5,482. CAT : A) <https://doi.org/10.1016/j.ygyno.2022.05.002>
3. Baboudjian, M., Beauval, J. B., Barret, E., Brureau, L., Créhange, G., Dariane, C., Fiard, G., Fromont, G., Gauthé, M., Mathieu, R., Renard-Penna, R., Roubaud, G., Ruffion, A., Sargos, P., Rouprêt, M., Ploussard, G., & Prostate Cancer Committee of the Association française d'urologie (CC-AFU) (2022). **[Recent advances in the management of localized high-risk prostate cancer: An update by the Prostate Cancer Committee of the French Association of Urology]**. *Progres en urologie : journal de l'Association française d'urologie et de la Société française d'urologie*, S1166-7087(22)00121-X. Advance online publication. (IF : 0.915. CAT : E) <https://doi.org/10.1016/j.purol.2022.04.007>
4. Baboudjian, M., Rajwa, P., Barret, E., Beauval, J. B., Brureau, L., Créhange, G., Dariane, C., Fiard, G., Fromont, G., Gauthé, M., Mathieu, R., Renard-Penna, R., Roubaud, G., Ruffion, A., Sargos, P., Rouprêt, M., Ploussard, G., & Prostate Cancer Committee of the Association Française d'Urologie CC-AFU (2022). **Vasectomy and Risk of Prostate Cancer: A Systematic Review and Meta-analysis.** *European urology open science*, 41, 35–44. (IF : 7,122. CAT : B) <https://doi.org/10.1016/j.euros.2022.04.012>
5. Bachelot, T., Cottu, P., Chabaud, S., Dalenc, F., Allouache, D., Delaloge, S., Jacquin, J. P., Grenier, J., Venat Bouvet, L., Jegannathan, A., Campone, M., Del Piano, F., Debled, M., Hardy-Bessard, A. C., Giacchetti, S., Mouret-Reynier, M. A., Barthelemy, P., Kaluzinski, L., Mailliez, A., Legouffe, E., ... Andre, F. (2022). **Everolimus Added to Adjuvant**

Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, JCO2102179. Advance online publication. (IF : 44,544. CAT : A) <https://doi.org/10.1200/JCO.21.02179>

6. Baldini, C., Charton, E., Schultz, E., Auroy, L., Italiano, A., Robert, M., Coquan, E., Isambert, N., Moreau, P., Le Gouill, S., Le Tourneau, C., Ghrieb, Z., Kiladjian, J. J., Delord, J. P., Roca, C. G., Vey, N., Barlesi, F., Lesimple, T., Penel, N., Soria, J. C., ... Besle, S. (2022). **Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.** *ESMO open*, 7(3), 100468. Advance online publication. (IF : 6,54. CAT : B) <https://doi.org/10.1016/j.esmoop.2022.100468>
7. Baudou, E., Pollidoro, L., Iannuzzi, S., Bertozzi, A. I., Tensaouti, F., Chaix, Y., & Laprie, A. (2022). **A review of long-term deficits in memory systems following radiotherapy for pediatric posterior fossa tumor.** *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*, S0167-8140(22)02278-2. Advance online publication. (IF : 6,28. CAT : B) <https://doi.org/10.1016/j.radonc.2022.05.022>
8. Bejarano-Quisoboni, D., Pelletier-Fleury, N., Allodji, R. S., Lacour, B., GrosClaude, P., FRANCIM Group, Pacquement, H., Doz, F., Berchery, D., Pluchart, C., Bondiau, P. Y., Nys, J., Jackson, A., Demoor-Goldschmidt, C., Dumas, A., Thomas-Teinturier, C., Vu-Bezin, G., Valteau-Couanet, D., Haddy, N., Fresneau, B., ... de Vathaire, F. (2022). **Health care expenditures among long-term survivors of pediatric solid tumors: Results from the French Childhood Cancer Survivor Study (FCCSS) and the French network of cancer registries (FRANCIM).** *PloS one*, 17(5), e0267317. (IF : 3,24. CAT : C) <https://doi.org/10.1371/journal.pone.0267317>
9. Bestvina, C. M., Whisenant, J. G., Torri, V., Cortellini, A., Wakelee, H., Peters, S., Roca, E., De Toma, A., Hirsch, F. R., Mamdani, H., Halmos, B., Arrieta, O., Metivier, A. C., Fidler, M. J., Rogado, J., Presley, C. J., Mascaux, C., Genova, C., Blaquier, J. B., Addeo, A., ... TERA-VOLT study group (2022). **COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related Delays during the Omicron Wave: A Brief Report from the TERA-VOLT Analysis.** *JTO clinical and research reports*, 100335. Advance online publication. (IF : NC. CAT : NC) <https://doi.org/10.1016/j.jtocr.2022.100335>
10. Bidard, F. C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M. A., Sohn, J. H., Taylor, D., Harnden, K. K., Khong, H., Kocsis, J., Dalenc, F., Dillon, P. M., Babu, S., Waters, S., Deleu, I., García Sáenz, J. A., Bria, E., Cazzaniga, M., ... Bardia, A. (2022). **Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, JCO2200338. Advance online publication. (IF : 44,544. CAT : A) <https://doi.org/10.1200/JCO.22.00338>
11. Bizzarri, N., Loverro, M., Angeles, M. A., Pedone Anchorà, L., Fagotti, A., Fanfani, F., Ferrandina, G., Scambia, G., & Querleu, D. (2022). **Laparoscopic Ovarian Transposition with Extraperitonealization of the Infundibulopelvic Ligament for**

Cervical Cancer in Ten Steps. *Annals of surgical oncology*, 10.1245/s10434-022-11870-0. Advance online publication. (IF : 5,344. CAT : A)
<https://doi.org/10.1245/s10434-022-11870-0>

12. Bonnet, A., Bossard, C., Gabellier, L., Rohmer, J., Laghmari, O., Parrens, M., Sarkozy, C., Dulery, R., Roland, V., Llamas-Gutierrez, F., Oberic, L., Fornecker, L. M., Bounaix, L., Villemagne, B., Szablewski, V., Choquet, S., Bouabdallah, K., Traverse-Glehen, A., Mohty, M., Sanhes, L., ... Le Gouill, S. (2022). **Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.** *Cancer medicine*, 10.1002/cam4.4742. Advance online publication. (IF : 4,452. CAT : C)
<https://doi.org/10.1002/cam4.4742>
13. Chalayer, E., Talbot, A., Frenzel, L., Karlin, L., Collet, P., Guyotat, D., Attal, M., Leleu, X., & Tardy, B. (2022). **Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.** *Journal of thrombosis and haemostasis : JTH*, 10.1111/jth.15758. Advance online publication. (IF : 5,824. CAT : B) <https://doi.org/10.1111/jth.15758>
14. Charra-Brunaud, C., Salleron, J., Menoux, I., Peignaux, K., Ducassou, A., Petit, A., Pommier, P., Barillot, I., Serre, A. A., Thomas, L., Delannes, M., Thibouw, D., Antoni, D., Renard, S., & Peiffert, D. (2022). **[Dose optimization in 3D pulsed dose rate brachytherapy for patients with locally advanced cervical cancer: A French multicenter phase II trial].** *Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique*, 26(3), 474–480. (IF : 1,018. CAT : E)
<https://doi.org/10.1016/j.canrad.2021.06.030>
15. Cordelier, P., Costa, M., & Fehrenbach, J. (2022). Slow-Fast Model and Therapy Optimization for Oncolytic Treatment of Tumors. *Bulletin of mathematical biology*, 84(6), 64. (IF : 1,758. CAT : D) <https://doi.org/10.1007/s11538-022-01025-3>
16. Cristini, A., Tellier, M., Constantinescu, F., Accalai, C., Albulescu, L. O., Heiringhoff, R., Bery, N., Sordet, O., Murphy, S., & Gromak, N. (2022). **RNase H2, mutated in Aicardi-Goutières syndrome, resolves co-transcriptional R-loops to prevent DNA breaks and inflammation.** *Nature communications*, 13(1), 2961. (IF : 14,919. CAT : A)
<https://doi.org/10.1038/s41467-022-30604-0>
17. Daix, M., Martinez Gomez, C., Angeles, M. A., Tock, S., Gladieff, L., Gabiache, E., Mery, E., Martinez, A., Cibula, D., & Ferron, G. (2022). **Extended pelvic resection for gynecological malignancies: A review of out-of-the-box surgery.** *Gynecologic oncology*, 165(2), 393–400. (IF : 5,482. CAT : A)
<https://doi.org/10.1016/j.ygyno.2022.03.002>
18. Darmon-Novello, M., Adam, J., Lamant, L., Battistella, M., Ortonne, N., Balme, B., de la Fouchardière, A., Chaltiel, L., Gerard, E., Franchet, C., & Vergier, B. (2022). **Harmonization of programmed death-ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis.** *Histopathology*, 80(7), 1091–1101. (IF : 5,087. CAT : B)
<https://doi.org/10.1111/his.14651>

19. Delahaye, C., Figarol, S., Pradines, A., Favre, G., Mazieres, J., & Calvayrac, O. (2022). **Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer.** *Cancers*, 14(11), 2613. (IF : 6,639. CAT : B) <https://doi.org/10.3390/cancers14112613>
20. Delaloge, S., Dureau, S., D'Hondt, V., Desmoulins, I., Heudel, P. E., Duhoux, F. P., Levy, C., Lerebours, F., Mouret-Reynier, M. A., Dalenc, F., Frenel, J. S., Jouannaud, C., Venat-Bouvet, L., Nguyen, S., Callens, C., Gentien, D., Rapinat, A., Manduzio, H., Vincent-Salomon, A., Lemonnier, J., ... French Breast cancer Intergroup Unicancer-UCBG (2022). **Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.** *European journal of cancer (Oxford, England : 1990)*, 166, 300–308. (IF : 9,162. CAT : B) <https://doi.org/10.1016/j.ejca.2022.01.014>
21. Dulucq, S., Nicolini, F. E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., Guerci-Bresler, A., Legros, L., Ianotto, J. C., Gardembas, M., Turlure, P., Dubrulle, V., Rousselot, P., Martiniuc, J., Jardel, H., Johnson-Ansah, H., ... Etienne, G. (2022). **Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.** *Haematologica*, 10.3324/haematol.2022.280811. Advance online publication. (IF : 9,941. CAT : A) <https://doi.org/10.3324/haematol.2022.280811>
22. Dummer, R., Long, G. V., Robert, C., Tawbi, H. A., Flaherty, K. T., Ascierto, P. A., Nathan, P. D., Rutkowski, P., Leonov, O., Dutriaux, C., Mandalà, M., Lorigan, P., Ferrucci, P. F., Grob, J. J., Meyer, N., Gogas, H., Stroyakovskiy, D., Arance, A., Brase, J. C., Green, S., ... Schadendorf, D. (2022). **Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 40(13), 1428–1438. (IF : 44,544. CAT : A) <https://doi.org/10.1200/JCO.21.01601>
23. Fayet, Y., Chevreau, C., Decanter, G., Dalban, C., Meeus, P., Carrère, S., Haddag-Miliani, L., Le Loarer, F., Causeret, S., Orbach, D., Kind, M., Le Nail, L. R., Ferron, G., Labrosse, H., Chaigneau, L., Bertucci, F., Ruzic, J. C., Le Brun Ly, V., Farsi, F., Bompas, E., ... Blay, J. Y. (2022). **No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks' Outcome?** *Cancers*, 14(11), 2620. (IF : 6,639. CAT : B) <https://doi.org/10.3390/cancers14112620>
24. Gaillard, T., Carton, M., Mailliez, A., Desmoulins, I., Mouret-Reynier, M. A., Petit, T., Leheurteur, M., Dieras, V., Ferrero, J. M., Uwer, L., Guiu, S., Gonc Alves, A., Levy, C., Debled, M., Dalenc, F., Patsouris, A., Bachelot, T., Eymard, J. C., Chevrot, M., Conversano, A., ... Hequet, D. (2022). **Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis"** [Eur J Cancer 158 (2021) 181-188]. *European journal of cancer (Oxford, England : 1990)*, 166, 311–312. (IF : 9,162. CAT : B) <https://doi.org/10.1016/j.ejca.2022.02.021>
25. Galvin, A., Bertrand, N., Boulahssass, R., De Decker, L., Dorval, É., Clairaz, B., Castaignède, M., Mourey, L., Baldini, C., Bauvin, E., Jacques, B., Mallon, I., Durand-

- Zaleski, I., Guérin, O., Krouri, S., & Soubeyran, P. (2022). **[Rethinking the management of elderly cancer patients : Proposals from the Age Cancer Priorities French Group]**. *Bulletin du cancer*, 109(6), 714–721. (IF : 1,276. CAT : E) <https://doi.org/10.1016/j.bulcan.2022.03.013>
26. Garnier, L., Vidal, C., Chinot, O., Cohen-Jonathan Moyal, E., Djelad, A., Bronnimann, C., Bekaert, L., Taillandier, L., Frenel, J. S., Langlois, O., Colin, P., Menei, P., Dhermain, F., Carpentier, C., Gerazime, A., Curtit, E., Figarella-Branger, D., Dehais, C., & Ducray, F. (2022). **Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study**. *The oncologist*, 27(5), 414–423. (IF : 5,55. CAT : C) <https://doi.org/10.1093/oncolo/oyac023>
27. Gomez-Roca, C., Cassier, P., Zamarin, D., Machiels, J. P., Luis Perez Gracia, J., Stephen Hodi, F., Taus, A., Martinez Garcia, M., Boni, V., Eder, J. P., Hafez, N., Sullivan, R., Mcdermott, D., Champiat, S., Aspeslagh, S., Terret, C., Jegg, A. M., Jacob, W., Cannarile, M. A., Ries, C., ... Marabelle, A. (2022). **Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade**. *Journal for immunotherapy of cancer*, 10(5), e004076. (IF : 13,751. CAT : A) <https://doi.org/10.1136/jitc-2021-004076>
28. Hamimed, M., Gattacceca, F., André, N., Tresch-Bruneel, E., Probst, A., Chastagner, P., Pagnier, A., De Carli, E., Entz-Werlé, N., Grill, J., Aerts, I., Frappaz, D., Bertozzi-Salamon, A. I., Solas, C., & Leblond, P. (2022). **Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma**. *British journal of clinical pharmacology*, 88(5), 2096–2117. (IF : 4,335. CAT : C) <https://doi.org/10.1111/bcp.15131>
29. Italiano, A., Bessede, A., Pulido, M., Bompas, E., Piperno-Neumann, S., Chevreau, C., Penel, N., Bertucci, F., Toulmonde, M., Bellera, C., Guegan, J. P., Rey, C., Sautès-Fridman, C., Bougoüin, A., Cantarel, C., Kind, M., Spalato, M., Dadone-Montaudie, B., Le Loarer, F., Blay, J. Y., ... Fridman, W. H. (2022). **Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort**. *Nature medicine*, 10.1038/s41591-022-01821-3. Advance online publication. (IF : 53,44. CAT : A) <https://doi.org/10.1038/s41591-022-01821-3>
30. Jackson, R., Chabrillac, E., Bell, A., & Edafe, O. (2022). **Rigid versus flexible endoscopy for managing ingested foreign bodies-can we improve pathways?** *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery*, 279(5), 2695–2700. (IF : 2,503. CAT : C) <https://doi.org/10.1007/s00405-022-07285-y>
31. Johnson, B. E., Baik, C. S., Mazieres, J., Groen, H., Melosky, B., Wolf, J., Zadeh Vosta Kolaei, F. A., Wu, W. H., Knoll, S., Ktiouet Dawson, M., Johns, A., & Planchard, D. (2022). **Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC**. *JTO clinical and research reports*, 3(5), 100324. (IF : NC. CAT : NC) <https://doi.org/10.1016/j.jtocrr.2022.100324>

32. Jonas, B. A., Wei, A. H., Recher, C., DiNardo, C. D., Jang, J. H., Pratz, K., Panayiotidis, P., Montesinos, P., Yeh, S. P., Ivanov, V., Fiedler, W., Yamauchi, T., Duan, Y., Mendes, W., Potluri, J., Tews, B., & Ofran, Y. (2022). **Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.** *American journal of hematology*, 10.1002/ajh.26600. Advance online publication. (IF : 10,047. CAT : A) <https://doi.org/10.1002/ajh.26600>
33. Kervarrec, T., Pissaloux, D., Poilane, J., Tirode, F., Tallet, A., Collin, C., Tallegas, M., Berthon, P., Gaboriaud, P., Sohier, P., Calonje, E., Luzar, B., Goto, K., Cokelaere, K., Lamant, L., Balme, B., Wild, R., Neuville, A., Deschamps, L., Auberger, E., ... Jullie, M. L. (2022). **Recurrent FOXK1::GRHL and GPS2::GRHL fusions in trichogerminoma.** *The Journal of pathology*, 257(1), 96–108. (IF : 7,996. CAT : A) <https://doi.org/10.1002/path.5872>
34. Konstantinou, M. P., & Tournier, E. (2022). **Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate.** *International journal of dermatology*, 10.1111/ijd.16269. Advance online publication. (IF : 2,736. CAT : D) <https://doi.org/10.1111/ijd.16269>
35. Lafuente-Ibáñez de Mendoza, I., Vigarios, E., Herbault-Barres, B., Alberdi-Navarro, J., Sibaud, V., Maret, D., & Aguirre-Urizar, J. M. (2022). **Non-infectious granulomatous disorders of the upper lip: clinicopathological analysis of 11 patients.** *BMC oral health*, 22(1), 173. (IF : 2,757. CAT : C) <https://doi.org/10.1186/s12903-022-02189-z>
36. Landgren, O., Kazandjian, D., Roussel, M., Jasielec, J., Dytfeld, D., Anderson, A., Kervin, T. A., Iskander, K., McFadden, I., & Jakubowiak, A. J. (2022). **Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies.** *Leukemia & lymphoma*, 1–9. Advance online publication. (IF : 3,28. CAT : D) <https://doi.org/10.1080/10428194.2022.2068001>
37. Lapierre, A., Hennequin, C., Beneux, A., Belhomme, S., Benziane Ouaritini, N., Biston, M. C., Crehange, G., de Crevoisier, R., Dumas, J. L., Fawzi, M., Lisbona, A., Pasquier, D., Pelissier, S., Graff-Cailleaud, P., Pommier, P., Sargos, P., Simon, J. M., Supiot, S., Tantot, F., & Chapet, O. (2022). **Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group.** *Critical reviews in oncology/hematology*, 173, 103661. (IF : 6,312. CAT : B) <https://doi.org/10.1016/j.critrevonc.2022.103661>
38. Leleu, T., Bastit, V., Doré, M., Kammerer, E., Florescu, C., Alfonsi, M., Troussier, I., Bensadoun, R. J., Biau, J., Blais, E., Coutte, A., Deberne, M., Wiazzane, N., Dupin, C., Faivre, J. C., Giraud, P., Graff, P., Guihard, S., Huguet, F., Janoray, G., ... Thariat, J. (2022). **Histosurgical mapping of endoscopic endonasal surgery of sinonasal tumours to improve radiotherapy guidance.** *Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique*, 26(3), 440–444. (IF : 1,018. CAT : E) <https://doi.org/10.1016/j.canrad.2021.06.014>
39. Lonati, C., Afferi, L., Mari, A., Minervini, A., Krajewski, W., Borghesi, M., Schulz, G. B., Rink, M., Montorsi, F., Briganti, A., Colombo, R., Martini, A., Necchi, A., Contieri, R., Hurle, R., Umari, P., Zamboni, S., Simeone, C., Soria, F., Marra, G., ... European Association of Urology—Young Academic Urologists (EAU-YAU): Urothelial Carcinoma

Working Group (2022). **Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.** *World journal of urology*, 40(5), 1167–1174. (IF : 4,226. CAT : B) <https://doi.org/10.1007/s00345-022-03958-9>

40. Lorient, Y., Texier, M., Culine, S., Fléchon, A., Thiery-Vuillemin, A., Gravis, G., Geoffrois, L., Chevreau, C., Gross-Goupil, M., Barthelemy, P., Bompas, E., Mahammed, H., Laguerre, B., Lacourtoisie, S. A., Helissey, C., Ladoire, S., Abraham, C., Massard, C., Grimaldi, S., & Fizazi, K. (2022). **The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.** *European urology*, S0302-2838(22)02330-2. Advance online publication. (IF : 20,096. CAT : A) <https://doi.org/10.1016/j.eururo.2022.04.031>
41. Marabelle, A., Cassier, P. A., Fakih, M., Kao, S., Nielsen, D., Italiano, A., Guren, T. K., van Dongen, M., Spencer, K., Bariani, G. M., Ascierto, P. A., Santoro, A., Shah, M., Asselah, J., Iqbal, S., Takahashi, S., Piha-Paul, S. A., Ott, P. A., Chatterjee, A., Jin, F., ... Delord, J. P. (2022). **Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.** *The lancet. Gastroenterology & hepatology*, 7(5), 446–454. (IF : 18,486. CAT : A) [https://doi.org/10.1016/S2468-1253\(21\)00382-4](https://doi.org/10.1016/S2468-1253(21)00382-4)
42. Martini, A., & Bravi, C. A. (2022). **Acute kidney injury and functional outcomes after partial nephrectomy.** *International journal of urology : official journal of the Japanese Urological Association*, 10.1111/iju.14939. Advance online publication. (IF : 3,369. CAT : C) <https://doi.org/10.1111/iju.14939>
43. Mazerolle, P., Fuchsmann, C., Schultz, P., Benmoussa, N., Malard, O., Bozec, A., Deneuve, S., Folia, M., Perréard, M., Lasne-Cardon, A., Chabrilac, E., Vergez, S., Chaltiel, L., & Dupret-Bories, A. (2022). **Salvage total glossectomy and total glosso-laryngectomy: Are they worth it? A GETTEC French multicenter study.** *Oral oncology*, 130, 105896. (IF : 5,337. CAT : A) <https://doi.org/10.1016/j.oraloncology.2022.105896>
44. McKenzie, B., Khazen, R., & Valitutti, S. (2022). **Greek Fire, Poison Arrows, and Scorpion Bombs: How Tumor Cells Defend Against the Siege Weapons of Cytotoxic T Lymphocytes.** *Frontiers in immunology*, 13, 894306. (IF : 7,561. CAT : B) <https://doi.org/10.3389/fimmu.2022.894306>
45. Mermier, M., Baron, P., Roumiguié, M., Bajeot, A. S., Pignot, G., Lannes, F., Ploussard, G., Gasmi, A., Bensalah, K., Perrot, O., Rouprêt, M., Bruyère, F., Pradere, B., & Verhoest, G. (2022). **Predictive Factors of Early Postoperative Complications After Robot-Assisted Radical Cystectomy for Urothelial Bladder Carcinoma.** *Journal of endourology*, 36(5), 634–640. (IF : 2,942. CAT : C) <https://doi.org/10.1089/end.2021.0617>
46. Meyer, N., Pérol, D., Duval-Modeste, A. B., El Adaoui, L., Lelarge, Y., Niarra, R., & Mateus, C. (2022). **Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.** *Melanoma research*, 10.1097/CMR.0000000000000833.

Advance online publication. (IF : 3,599. CAT : C)

<https://doi.org/10.1097/CMR.0000000000000833>

47. Michallet, M., Sobh, M., Morisset, S., Deloire, A., Raffoux, E., de Botton, S., Caillot, D., Chantepeie, S., Girault, S., Berthon, C., Bertoli, S., Lepretre, S., Leguay, T., Castaigne, S., Marolleau, J. P., Pautas, C., Malfuson, J. V., Veyn, N., Braun, T., Gastaud, L., ... Bergeron, A. (2022). **Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.** *Clinical lymphoma, myeloma & leukemia*, 22(5), 311–318. (IF : 3,231. CAT : D) <https://doi.org/10.1016/j.clml.2021.10.011>
48. Mogenet, A., Barlesi, F., Besse, B., Michiels, S., Karimi, M., Tran-Dien, A., Girard, N., Mazieres, J., Audigier-Valette, C., Locatelli-Sanchez, M., Kamal, M., Gestraud, P., Hamza, A., Jacquet, A., Jimenez, M., Yara, S., Greillier, L., Bertucci, F., Planchard, D., Soria, J. C., ... Tomasini, P. (2022). **Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome.** *Lung cancer (Amsterdam, Netherlands)*, 169, 31–39. Advance online publication. (IF : 5,705. CAT : B) <https://doi.org/10.1016/j.lungcan.2022.05.004>
49. Morfouace, M., Novello, S., Stevovic, A., Dooms, C., Janžič, U., Berghmans, T., Dziadziuszko, R., Gorlia, T., Felip, E., Paz-Ares, L., Mazieres, J., O'Brien, M., Bironzo, P., Vansteenkiste, J., Lacroix, L., Dingemans, A. C., Golfopoulou, V., & Besse, B. (2022). **Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTALung platform.** *Scientific reports*, 12(1), 8342. (IF : 4,379. CAT : B) <https://doi.org/10.1038/s41598-022-12056-0>
50. Paiva, B., San-Miguel, J. F., & Avet-Loiseau, H. (2022). **MRD in multiple myeloma: does CR really matter?** *Blood*, blood.2022016170. Advance online publication. (IF : 22,113. CAT : A) <https://doi.org/10.1182/blood.2022016170>
51. Péan de Ponfilly-Sotier, M., Jachiet, V., Benhamou, Y., Lahuna, C., De Renzis, B., Kottler, D., Voillat, L., Dimicoli-Salazar, S., Banos, A., Chauveheid, M. P., Alexandra, J. F., Grignano, E., Liferman, F., Laborde, M., Broner, J., Michel, M., Lambotte, O., Laribi, K., Venon, M. D., Dussol, B., ... MINHEMON (French Network of Dysimmune Disorders Associated with Hemopathies) and GFM (2022). **Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.** *Clinical and experimental rheumatology*, 10.55563/clinexprheumatol/nbn38d. Advance online publication. (IF : 4,473. CAT : C) <https://doi.org/10.55563/clinexprheumatol/nbn38d>
52. Perl, A. E., Hosono, N., Montesinos, P., Podoltsev, N., Martinelli, G., Panoskaltsis, N., Recher, C., Smith, C. C., Levis, M. J., Strickland, S., Röhlig, C., Groß-Langenhoff, M., Chou, W. C., Lee, J. H., Yokoyama, H., Hasabou, N., Lu, Q., Tiu, R. V., & Altman, J. K. (2022). **Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.** *Blood cancer journal*, 12(5), 84. (IF : 11,037. CAT : A) <https://doi.org/10.1038/s41408-022-00677-7>

53. Perrot A. (2022). How I treat frontline transplantation-eligible multiple myeloma. *Blood*, 139(19), 2882–2888. (IF : 22,113. CAT : A) <https://doi.org/10.1182/blood.2020008735>
54. Rahota, R. G., Diamand, R., Malavaud, B., Fiard, G., Descotes, J. L., Peltier, A., Beauval, J. B., Roumeguère, T., Roumigué, M., Albisinni, S., & Ploussard, G. (2022). **Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.** *BJU international*, 129(5), 621–626. (IF : 5,588. CAT : B) <https://doi.org/10.1111/bju.15563>
55. Rossi, C., André, M., Dupuis, J., Morschhauser, F., Joly, B., Lazarovici, J., Ghesquières, H., Stamatoullas, A., Nicolas-Virelizier, E., Feugier, P., Gac, A. C., Moatti, H., Fornecker, L. M., Deau, B., Joubert, C., Fortpied, C., Raemaekers, J., Federico, M., Kanoun, S., Meignan, M., ... Casasnovas, R. O. (2022). **High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.** *Haematologica*, 10.3324/haematol.2021.280004. Advance online publication. (IF : 9,941. CAT : A) <https://doi.org/10.3324/haematol.2021.280004>
56. Roussel, M., Lauwers-Cances, V., Macro, M., Leleu, X., Royer, B., Hulin, C., Karlin, L., Perrot, A., Touzeau, C., Chrétien, M. L., Rigaudeau, S., Dib, M., Nicolas-Virelizier, E., Escoffre-Barbe, M., Belhadj, K., Mariette, C., Stoppa, A. M., Araujo, C., Doyen, C., Fontan, J., ... Attal, M. (2022). **Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.** *Blood*, 139(18), 2747–2757. (IF : 22,113. CAT : A) <https://doi.org/10.1182/blood.2021014635>
57. Sabatier, R., Vicier, C., Garnier, S., Guille, A., Carbuccion, N., Isambert, N., Dalenc, F., Robert, M., Levy, C., Pakradouni, J., Adelaïde, J., Chaffanet, M., Sfumato, P., Mamessier, E., Bertucci, F., & Goncalves, A. (2022). **Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.** *Molecular oncology*, 16(10), 2057–2070. (IF : 6,603. CAT : B) <https://doi.org/10.1002/1878-0261.13188>
58. Seiler, K., Humbert, M., Minder, P., Mashimo, I., Schläfli, A. M., Krauer, D., Federzoni, E. A., Vu, B., Moresco, J. J., Yates, J. R., 3rd, Sadowski, M. C., Radpour, R., Kaufmann, T., Sarry, J. E., Dengjel, J., Tschan, M. P., & Torbett, B. E. (2022). **Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions.** *Cell death & disease*, 13(5), 448. (IF : 8,469. CAT : B) <https://doi.org/10.1038/s41419-022-04891-w>
59. Tauziède-Espariat, A., Siegfried, A., Nicaise, Y., Figarella-Branger, D., Appay, R., Senova, S., Bochaton, D., Hasty, L., Martin, A., Chrétien, F., Métais, A., Varlet, P., Uro-Coste, E., & RENOCIP-LOC (2022). **A novel YAP1-MAML2 fusion in an adult supra-tentorial ependymoma, YAP1-fused.** *Brain tumor pathology*, 10.1007/s10014-022-00439-0. Advance online publication. (IF : 3,298. CAT : C) <https://doi.org/10.1007/s10014-022-00439-0>
60. Vabre, C., Zelmat, Y., Gauthier, M., Pajiepe, M., Conte, C., Lapeyre-Mestre, M., Dray-Spira, R., Zureik, M., & Despas, F. (2022). **Incident users of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: Analysis of anticancer treatment trajectories-A French population-based study using the French national health**

data system. *American journal of hematology*, 10.1002/ajh.26621. Advance online publication. (IF : 10,047. CAT : A) <https://doi.org/10.1002/ajh.26621>

61. Vano, Y. A., Elaidi, R., Bennamoun, M., Chevreau, C., Borchiellini, D., Pannier, D., Maillet, D., Gross-Goupil, M., Tournigand, C., Laguerre, B., Barthélémy, P., Coquan, E., Gravis, G., Houede, N., Cancel, M., Huillard, O., Beuzeboc, P., Fournier, L., Méjean, A., Cathelineau, X., ... Oudard, S. (2022). **Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.** *The Lancet. Oncology*, 23(5), 612–624. (IF : 41,316. CAT : A) [https://doi.org/10.1016/S1470-2045\(22\)00128-0](https://doi.org/10.1016/S1470-2045(22)00128-0)
62. Vano, Y. A., Phan, L., Gravis, G., Korakis, I., Schlürmann, F., Maillet, D., Bennamoun, M., Houede, N., Topart, D., Borchiellini, D., Barthelemy, P., Ratta, R., Ryckewaert, T., Hasbini, A., Hans, S., Emambux, S., Cournier, S., Braychenko, E., Elaidi, R. T., & Oudard, S. (2022). **Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.** *International journal of cancer*, 10.1002/ijc.34126. Advance online publication. (IF : 7,396. CAT : B) <https://doi.org/10.1002/ijc.34126>
63. Vigarios, E., Warnakulasuriya, S., Piau, A., Giraudeau, N., & Maret, D. (2022). **Early detection of oral malignancies may involve the development of tele-expertise in dentistry.** *Oral oncology*, 130, 105904. (IF : 5,337. CAT : A) <https://doi.org/10.1016/j.oraloncology.2022.105904>
64. Whisenant, J. G., Baena, J., Cortellini, A., Huang, L. C., Lo Russo, G., Porcu, L., Wong, S. K., Bestvina, C. M., Hellmann, M. D., Roca, E., Rizvi, H., Monnet, I., Boudjemaa, A., Rogado, J., Pasello, G., Leighl, N. B., Arrieta, O., Aujayeb, A., Batra, U., Azzam, A. Y., ... TERA-VOLT study group (2022). **A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERA-VOLT Registry.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*, 17(5), 661–674. (IF : 15,609. CAT : A) <https://doi.org/10.1016/j.jtho.2021.12.015>

